Shares of PAREXEL International Co. (NASDAQ:PRXL) have earned an average recommendation of “Hold” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $76.81.

A number of analysts have recently issued reports on PRXL shares. Zacks Investment Research raised PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Tuesday, August 8th. BidaskClub cut PAREXEL International from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th.

COPYRIGHT VIOLATION WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/11/02/parexel-international-co-prxl-given-consensus-recommendation-of-hold-by-brokerages.html.

A number of large investors have recently added to or reduced their stakes in the stock. World Asset Management Inc lifted its holdings in PAREXEL International by 0.3% during the 2nd quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock worth $279,000 after purchasing an additional 9 shares during the last quarter. 1st Global Advisors Inc. lifted its holdings in PAREXEL International by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock worth $469,000 after purchasing an additional 21 shares during the last quarter. Amalgamated Bank lifted its holdings in PAREXEL International by 0.6% during the 2nd quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock worth $631,000 after purchasing an additional 42 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in PAREXEL International by 4.5% during the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after purchasing an additional 73 shares during the last quarter. Finally, Texas Permanent School Fund lifted its holdings in PAREXEL International by 0.5% during the 2nd quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock worth $3,221,000 after purchasing an additional 169 shares during the last quarter. 87.45% of the stock is owned by institutional investors and hedge funds.

PAREXEL International (NASDAQ:PRXL) last posted its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. The firm had revenue of $557.20 million during the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. During the same period last year, the company earned $0.94 earnings per share.

PAREXEL International Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Analyst Recommendations for PAREXEL International (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.